720 related articles for article (PubMed ID: 23441529)
1. [Opatija study: observation of hemodialysis patients and titration of CERA dose just switched from another erythropoiesis stimulating agent].
Jelić I; Lovcić V; Kurtović I; Josipović M; Havranek Z; Kostić L; Racki S
Acta Med Croatica; 2012 Jul; 66(3):157-64. PubMed ID: 23441529
[TBL] [Abstract][Full Text] [Related]
2. Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.
Kawai T; Kusano Y; Yamada K; Ueda C; Kawai A; Masaki T
J Artif Organs; 2019 Jun; 22(2):146-153. PubMed ID: 30426250
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of a simple dosage scheme to convert from shorter-acting erythropoiesis-stimulating agent to continuous erythropoietin receptor activator in kidney transplantation patients.
Sánchez-Escuredo A; Batista F; Cases A; Torregrosa JV
Transplant Proc; 2015; 47(1):73-5. PubMed ID: 25645774
[TBL] [Abstract][Full Text] [Related]
4. Hemoglobin variability with epoetin beta and continuous erythropoietin receptor activator in patients on peritoneal dialysis.
Selby NM; Fonseca SA; Fluck RJ; Taal MW
Perit Dial Int; 2012; 32(2):177-82. PubMed ID: 22045101
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of CERA in anemia correction in predialysis patients--Croatian experience].
Bubić I; Prkacin I; Racki S
Acta Med Croatica; 2012 Oct; 66 Suppl 2():42-6. PubMed ID: 23513415
[TBL] [Abstract][Full Text] [Related]
6. Hemoglobin maintenance and dosing strategies using intravenous continuous erythropoietin receptor activator in Japanese hemodialysis patients.
Hirai T; Nishizawa Y; Nakazono H; Asai M; Yamashita H; Sasaki A; Yamashita T; Yamashita K; Shigemoto K; Harada S; Mizuiri S
Ther Apher Dial; 2013 Oct; 17(5):498-503. PubMed ID: 24107278
[TBL] [Abstract][Full Text] [Related]
7. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator.
Yoshida T; Hayashi M
Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008
[TBL] [Abstract][Full Text] [Related]
8. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.
Fischbach M; Wühl E; Reigner SCM; Morgan Z; Schaefer F
Clin J Am Soc Nephrol; 2018 Jan; 13(1):81-90. PubMed ID: 29097481
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Methoxy Polyethylene Glycol-epoetin Beta in Anemia Treatment in Patients on Hemodialysis: a Macedonian Experience.
Kacarska-Fotevska II; Volckova N; Ilievska K; Donev D
Med Arch; 2020 Apr; 74(2):109-114. PubMed ID: 32577051
[TBL] [Abstract][Full Text] [Related]
11. Subcutaneous C.E.R.A. for the Maintenance Treatment of Anemia in Pediatric Patients With CKD: A Phase 2, Open-Label, Single-Arm, Multicenter Study.
Warady BA; Meyer Reigner S; Tirodkar C; Drozdz D
Am J Kidney Dis; 2023 Jun; 81(6):684-694.e1. PubMed ID: 36587890
[TBL] [Abstract][Full Text] [Related]
12. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
13. Treatment of renal anaemia with erythropoiesis-stimulating agents in predialysis chronic kidney disease patients: Haemoglobin profile during the 6 months before initiation of dialysis.
Kawahara K; Minakuchi J; Yokota N; Suekane H; Tsuchida K; Kawashima S
Nephrology (Carlton); 2015 Dec; 20 Suppl 4():29-32. PubMed ID: 26456375
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
15. A randomized control study on the procedure for switching epoetin beta (EPO) to epoetin beta pegol (CERA) in the treatment of renal anemia in maintenance hemodialysis patients.
Toida T; Sato Y; Shibata N; Kitamura K; Fujimoto S
Blood Purif; 2014; 38(3-4):174-9. PubMed ID: 25502179
[TBL] [Abstract][Full Text] [Related]
16. Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.
Fuller DS; Robinson BM; Locatelli F; Pisoni RL
Nephron; 2018; 140(1):24-30. PubMed ID: 29945128
[TBL] [Abstract][Full Text] [Related]
17. Impact of Switching From Darbepoetin Alfa to Epoetin Beta Pegol on Iron Utilization and Blood Pressure in Peritoneal Dialysis Patients.
Washida N; Inoue S; Kasai T; Shinozuka K; Hosoya K; Morimoto K; Wakino S; Hayashi K; Itoh H
Ther Apher Dial; 2015 Oct; 19(5):450-6. PubMed ID: 25944557
[TBL] [Abstract][Full Text] [Related]
18. Effect of conversion from ESA with shorter half-life to CERA once monthly for maintaining Hb concentration in pre-dialysis CKD patients.
Choi JY; Yang CW; Kim YH; Joo KW; Yoo TH; Lee KW; Lee SH; Moon JY; Shin SK; Huh W; Kim NH; Park SH; Kim CD; Kim YL
Kidney Blood Press Res; 2013; 37(4-5):259-68. PubMed ID: 24022228
[TBL] [Abstract][Full Text] [Related]
19. Individualized anemia management in a dialysis facility - long-term utility as a single-center quality improvement experience
.
Gaweda AE; Jacobs AA; Aronoff GR; Brier ME
Clin Nephrol; 2018 Oct; 90(4):276-285. PubMed ID: 30049300
[TBL] [Abstract][Full Text] [Related]
20. Changes in hepcidin and reticulocyte hemoglobin equivalent levels in response to continuous erythropoietin receptor activator administration in hemodialysis patients: a randomized study.
Kakimoto-Shino M; Toya Y; Kuji T; Fujikawa T; Umemura S
Ther Apher Dial; 2014 Oct; 18(5):421-6. PubMed ID: 24456328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]